Perrigo Co. PLC expects to offer Prevacid 24 HR in an orally disintegrating tablet following its purchase of the brand from GlaxoSmithKline PLC, its first deal since making a “nationally brand better” commitment.
For GSK, divesting US rights to Prevacid 24 HR leaves it with another proton pump inhibitor to treat for frequent heartburn in the consumer health portfolio under its control. The UK pharma will market Pfizer Inc